These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38494412)

  • 1. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Fierro C; Weidenthaler H; Vidojkovic S; Schmidt D; Gafoor Z; Stroukova D; Zwiers S; Müller J; Volkmann A
    Vaccine; 2024 Apr; 42(10):2695-2706. PubMed ID: 38494412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
    Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
    Front Immunol; 2020; 11():598847. PubMed ID: 33542715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses.
    Hu WG; Steigerwald R; Kalla M; Volkmann A; Noll D; Nagata LP
    Vaccine; 2018 Aug; 36(34):5194-5203. PubMed ID: 30037666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
    Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
    Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
    Reed DS; Glass PJ; Bakken RR; Barth JF; Lind CM; da Silva L; Hart MK; Rayner J; Alterson K; Custer M; Dudek J; Owens G; Kamrud KI; Parker MD; Smith J
    J Virol; 2014 Oct; 88(20):12077-86. PubMed ID: 25122801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.
    Rico AB; Phillips AT; Schountz T; Jarvis DL; Tjalkens RB; Powers AM; Olson KE
    Virology; 2016 Dec; 499():30-39. PubMed ID: 27632563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.
    Dupuy LC; Richards MJ; Livingston BD; Hannaman D; Schmaljohn CS
    J Immunol Res; 2018; 2018():8521060. PubMed ID: 29967804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Erasmus JH; Seymour RL; Kaelber JT; Kim DY; Leal G; Sherman MB; Frolov I; Chiu W; Weaver SC; Nasar F
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29187545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Western, Eastern, and Venezuelan Equine Encephalitis (WEVEE) Virus-Replicon Particle (VRP) Vaccine against WEEV in a Non-Human Primate Animal Model.
    Burke CW; Erwin-Cohen RA; Goodson AI; Wilhelmsen C; Edmundson JA; White CE; Glass PJ
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.
    Stromberg ZR; Fischer W; Bradfute SB; Kubicek-Sutherland JZ; Hraber P
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32503232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing multivalent immunogens for alphavirus vaccine optimization.
    Read CM; Plante K; Rafael G; Rossi SL; Braun W; Weaver SC; Schein CH
    Virology; 2021 Sep; 561():117-124. PubMed ID: 33823988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques.
    Beddingfield BJ; Plante KS; Plante JA; Weaver SC; Bose S; Krzykwa C; Chirichella N; Redmann RK; Seiler SZ; Dufour J; Blair RV; Endt K; Volkmann A; Maness NJ; Roy CJ
    NPJ Vaccines; 2024 Feb; 9(1):47. PubMed ID: 38413593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV.
    Phelps AL; O'Brien LM; Ulaeto DO; Holtsberg FW; Liao GC; Douglas R; Aman MJ; Glass PJ; Moyer CL; Ennis J; Zeitlin L; Nagata LP; Hu WG
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralising antibodies for Mayaro virus in Pantanal, Brazil.
    Pauvolid-Corrêa A; Juliano RS; Campos Z; Velez J; Nogueira RM; Komar N
    Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):125-33. PubMed ID: 25742272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pathology study of Venezuelan, eastern, and western equine encephalitis viruses in non-human primates.
    Smith DR; Schmaljohn CS; Badger C; Ostrowski K; Zeng X; Grimes SD; Rayner JO
    Antiviral Res; 2020 Oct; 182():104875. PubMed ID: 32755661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
    Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
    Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of Programmed -1 Ribosomal Frameshifting in Venezuelan Equine Encephalitis Virus Results in Attenuated Neuropathogenicity.
    Kendra JA; de la Fuente C; Brahms A; Woodson C; Bell TM; Chen B; Khan YA; Jacobs JL; Kehn-Hall K; Dinman JD
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.